NeoChord, Inc

NeoChord, Inc. is a privately held medical technology company specializing in beating heart mitral valve repair. The company manufactures the NeoChord Artificial Chordae Delivery System (Model DS1000), an echo-guided, minimally invasive treatment for patients with mitral valve regurgitation. The device enables direct repair of the mitral valve on a beating heart without requiring cardiopulmonary bypass, preserving the valve structure and future treatment options. The system uses artificial chords deployed via transapical access under echocardiographic guidance. NeoChord's technology improves procedural control, restores mitral valve function, and has been evaluated in multiple clinical studies across numerous countries. The company holds CE marking conformity under European Medical Device Regulation (MDR) 2017/745. In the United States, the device is investigational and limited to investigational use by federal law. NeoChord serves cardiac surgeons, interventional cardiologists, and cardiac care centers treating mitral valve disease. The company maintains a focus on clinical evidence generation, with multiple peer-reviewed publications documenting feasibility, safety, and efficacy of the procedure, including novel applications such as re-repair and use in complex anatomies.